Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.39 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3988680 | 0.85 | NOTUM (0.40) | NOTUMCYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL3989664 | 0.84 | NOTUM (0.40) | NOTUMCYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL18297330 | 0.84 | PDCD1LG2 (0.35) | PDCD1LG2CD274 | |
| SCHEMBL3982903 | 0.83 | NOTUM (0.38) | NOTUMCYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL3988673 | 0.83 | DRD2 (0.41) | NOTUMPDCD1LG2CD274 | |
| SCHEMBL3984247 | 0.83 | NOTUM (0.54) | NOTUMCYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL3989740 | 0.81 | F10 (0.34) | PDCD1LG2CD274 | |
| SCHEMBL4298416 | 0.81 | NOTUM (0.37) | NOTUMCYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL3983060 | 0.81 | NOTUM (0.37) | NOTUMCYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL3984226 | 0.80 | NOTUM (0.43) | NOTUMCYP2E1CYP2A6CYP2C9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893572-B1 | FACTOR XA INHIBITORS | MILLENNIUM PHARM INC (US) | 2016-12-14 | — | — | EP | claimed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | claimed |
| US-20060100193-A1 | 5-Chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)thiophene-2-carboxamide; 5-Chloro-thiophene-2-carboxylic acid (3-p-tolyl-4,5-dihydro-isoxazol-5-ylmethyl)-amide; undesirable thrombosis inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-11 | — | — | US | claimed |
| EP-1893572-B1 | FACTOR XA INHIBITORS | MILLENNIUM PHARM INC (US) | 2016-12-14 | — | — | EP | disclosed |
| US-8377974-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120178733-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-7521470-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| EP-1893572-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20060100193-A1 | 5-Chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)thiophene-2-carboxamide; 5-Chloro-thiophene-2-carboxylic acid (3-p-tolyl-4,5-dihydro-isoxazol-5-ylmethyl)-amide; undesirable thrombosis inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-11 | — | — | US | disclosed |
| WO-2006002099-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100193-A1 | 5-Chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)thiophene-2-carboxamide; 5-Chloro-thiophene-2-carboxylic acid (3-p-tolyl-4,5-dihydro-isoxazol-5-ylmethyl)-amide; undesirable thrombosis inhibitor | TFPI, TFPI2, F12 | NOTUM 1205/4885CYP2E1 74/4885CYP2A6 162/4885 |
| US-20090298806-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | NOTUM 578/4885CYP2E1 290/4885CYP2A6 172/4885 |
| US-20120178733-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | NOTUM 578/4885CYP2E1 290/4885CYP2A6 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.